Adamas to Announce Third Quarter 2020 Financial Results and Host Conference Call on November 5, 2020
Adamas Pharmaceuticals (Nasdaq: ADMS) will report its Q3 2020 financial results on November 5, 2020, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Adamas Pharmaceuticals (Nasdaq: ADMS) will report its Q3 2020 financial results on November 5, 2020, after market close. Following the financial report, a conference call will be held at 4:30 PM ET to discuss results and provide corporate updates. Investors can access the call by dialing (844) 215-3280 (U.S.) or (484) 747-6383 (international) using Conference ID: 1578986. A live webcast will be available on the Adamas website and will be accessible for replay until December 5, 2020.
Details
News Market Reaction – ADMS
The recorded move for ADMS in the trading session of this news was -0.57%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EMERYVILLE, Calif., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2020 third quarter financial results on Thursday, November 5, 2020, after market close. Subsequently, Adamas’ management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update.
Investor Conference Call and Webcast
The conference call can be accessed by dialing (844) 215-3280 for participants in the U.S. or Canada and (484) 747-6383 for international callers. All callers must provide the following Conference ID: 1578986. The webcast can be accessed live via the investor section of the Adamas website at https://ir.adamaspharma.com/events-presentations and will be available for replay until December 5, 2020.
About Adamas Pharmaceuticals, Inc.
At Adamas our vision is clear – to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. We are a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. For more information, please visit www.adamaspharma.com.
Contact
| Media: Sarah Mathieson Vice President, Corporate Communications 510-450-3528 smathieson@adamaspharma.com | Investors: Peter Vozzo Managing Director, Westwicke 443-213-0505 peter.vozzo@westwicke.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.